ZZM-1220
ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC50s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Histone Methyltransferase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zzm-1220.html
Purity
98.74
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(C2=NC3=CC(OC)=C(C=C3C(NC4CCN(CC4)C)=N2)OC)=CC=C1)=O
Molecular Formula
C25H29N5O3
Molecular Weight
447.53
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EHMT1/GLP/KMT1D; EHMT2/G9a/KMT1C
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PPP2R3B (Serine/Threonine-protein Phosphatase 2A Regulatory Subunit B'' Subunit beta, PP2A Subunit B Isoform PR48, Protein Phosphatase 2A 48kD Regulatory Subunit, PPP2R3L, FLJ60425, NYREN8, PPP2R3LY) (Biotin)
